Orally Disintegrating Tablet Global Market Report 2025
상품코드:1810983
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
구강붕해정 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 8.6%로 225억 3,000만 달러로 성장합니다. 예측기간의 성장은 만성질환 부담 증가, 셀프메디케이션 선호도 증가, 원격의료 및 전자약국 보급 확대, 맞춤형 의료에 대한 관심 증가, 채식주의자 및 알레르겐 프리 제제에 대한 수요 증가, 고령인구 증가 등에 기인하는 것으로 보입니다. 이 기간 중 예상되는 주요 동향으로는 다제 병용형 구강붕해정 개발, 디지털 헬스 플랫폼과의 통합, 안정성과 휴대성을 높이는 첨단 포장 혁신, 미각 마스킹 기술의 발전, 제형 기술의 발전 등이 있습니다.
신경질환의 유병률 증가는 향후 수년간 구강붕해정(ODT) 시장의 성장을 촉진할 것으로 예측됩니다. 신경질환은 뇌와 말초신경을 포함한 신경계에 영향을 미쳐 정상적인 기능을 방해하는 병입니다. 이러한 신경질환 증가는 알츠하이머병, 파킨슨병 등의 질환이 노화와 함께 만연하고 환자 수가 증가함에 따라 인구의 고령화가 주요 원인으로 작용하고 있습니다. 구강붕해정은 특히 연하장애(삼키기 어려운 상태)나 인지장애가 있는 환자들에게 보다 쉽고 빠르게 약을 복용할 수 있게 함으로써 신경질환 관리에 큰 이점을 제공합니다. 이 정제는 더 나은 치료 순응도를 지원하고, 적시에 복용할 수 있도록 도와주며, 치료의 전반적인 효과를 향상시킵니다. 예를 들어 2023년 3월 알츠하이머병 협회가 발표한 바에 따르면 65세 이상 알츠하이머형 치매를 앓고 있는 미국인은 약 670만 명이며, 이 수치는 2060년까지 1,380만 명으로 늘어날 것으로 예측됩니다. 그 결과, 신경질환의 유병률 증가는 구강붕해정 시장의 성장을 가속하고 있습니다.
구강붕해정 시장의 주요 기업은 치료 순응도와 결과를 개선하기 위해 약물 제제, 특히 환자 중심의 약물전달 시스템 혁신에 집중하고 있습니다. 환자 중심의 약물전달 시스템은 환자가 보다 쉽고 편안하게 약을 복용할 수 있도록 설계되어 전반적인 치료 경험과 순응도를 향상시킬 수 있습니다. 예를 들어 2025년 5월 미국 헬스케어 기업 비아트리스(Viatris Inc.)는 치료 저항성 정신분열증 환자에게 새로운 치료 옵션을 제공하는 젠크로자핀 구강붕해정(ODT)을 캐나다에서 출시했습니다. 이 약은 캐나다에서 최초로 출시된 ODT 제제로, 물을 필요로 하지 않고 구강 내에서 빠르게 용해되는 간편한 제형이기 때문에 삼키기 어려운 환자나 복용 순응도에 문제가 있는 환자들에게 특히 유용합니다. 본 제제는 다양한 용량(12.5mg, 25mg, 50mg, 100mg, 200mg)으로 출시되어 환자 개개인의 필요에 따라 유연하고 정확한 용량 증량 조절이 가능합니다. 치료 저항성 정신분열증에 대해 유일하게 승인된 항정신병 약물인 클로자핀을 사용한 이 ODT 제제는 확립된 임상 프로토콜에 부합하며, 환자 치료를 개선합니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 구강붕해정 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 구강붕해정 시장 : 성장률 분석
세계의 구강붕해정 시장 실적 : 규모와 성장, 2019-2024
세계의 구강붕해정 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 구강붕해정 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 구강붕해정 시장 : 약제 클래스별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
항정신병약
항간질약
중추 신경 자극약
항불안약
항파킨슨병약
강압제
비스테로이드성 항염증약
항알레르기약
프로톤 펌프 저해제
기타 약물 클래스
세계의 구강붕해정 시장 : 질환 적응증별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
중추신경계 질환
소화기 질환
심혈관계 질환
알레르기
기타 질환 적응증
세계의 구강붕해정 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
온라인 약국
소매 약국
드러그스토어
세계의 구강붕해정 시장 : 소비자 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
소아과
성인용
고령자
세계의 구강붕해정 시장 : 서브 세분화, 항정신병약(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
비정형 항정신병약
정형 항정신병약
세계의 구강붕해정 시장 : 서브 세분화, 항간질약(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
나트륨 채널 차단약
GABA 유사체
기타 항간질약
세계의 구강붕해정 시장 : 서브 세분화, 중추 신경 자극약(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
암페타민 유도체
메틸페니데이트
기타 중추 신경 자극약
세계의 구강붕해정 시장 : 서브 세분화, 항불안약(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
벤조디아제핀
비벤조디아제핀계 항불안약
세계의 구강붕해정 시장 : 서브 세분화, 항파킨슨병약(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
도파민 작용제
MAO-B 저해제
기타 항파킨슨병약
세계의 구강붕해정 시장 : 서브 세분화, 강압제(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
베타 차단약
칼슘 채널 차단약
ACE 저해제
세계의 구강붕해정 시장 : 서브 세분화, 비스테로이드성 항염증약(NSAIDs), 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
이부프로펜
디클로페낙
기타 NSAIDs
세계의 구강붕해정 시장 : 서브 세분화, 항알레르기약(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
항히스타민제
코르티코스테로이드
세계의 구강붕해정 시장 : 서브 세분화, 프로톤 펌프 저해제(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
Omeprazole
Esomeprazole
기타 PPI
세계의 구강붕해정 시장 : 서브 세분화, 기타 약물 클래스(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
항구토제
편두통약
기타 치료 클래스
제7장 지역별·국가별 분석
세계의 구강붕해정 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 구강붕해정 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
구강붕해정 시장 : 경쟁 구도
구강붕해정 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
Novartis AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Viatris Inc.
Teva Pharmaceutical Industries Ltd.
Otsuka Pharmaceutical Co Ltd.
Astellas Pharma Inc.
Daiichi Sankyo Company Limited
Sun Pharmaceutical Industries Limited
Aurobindo Pharma USA Inc.
Dr. Reddy's Laboratories Limited
Cadila Healthcare Limited
Torrent Pharmaceuticals Limited
Adare Pharma Solutions
KalVista Pharmaceuticals Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
구강붕해정 시장 2029 : 새로운 기회를 제공하는 국가
구강붕해정 시장 2029 : 새로운 기회를 제공하는 부문
구강붕해정 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
An orally disintegrating tablet (ODT) is a type of tablet designed to dissolve or break down quickly in the mouth without the need for water. It is especially helpful for patients who have difficulty swallowing, providing a convenient and easy-to-administer alternative to conventional tablets.
The main drug classes of orally disintegrating tablets include antipsychotics, antiepileptics, central nervous system stimulants, anxiolytics, anti-Parkinsonian drugs, antihypertensives, nonsteroidal anti-inflammatory drugs, antiallergy drugs, proton pump inhibitors, and others. Antipsychotics are medications used to treat mental health disorders by reducing symptoms such as hallucinations and delusions. These tablets address multiple disease indications including central nervous system diseases, gastrointestinal disorders, cardiovascular conditions, allergies, and more. They are distributed through various channels such as hospital pharmacies, online pharmacies, retail pharmacies, and drug stores, and serve diverse consumer groups, including pediatric, adult, and geriatric patients.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The orally disintegrating tablet market research report is one of a series of new reports from The Business Research Company that provides orally disintegrating tablet market statistics, including orally disintegrating tablet industry global market size, regional shares, competitors with an orally disintegrating tablet market share, orally disintegrating tablet market segments, market trends and opportunities, and any further data you may need to thrive in the orally disintegrating tablet industry. This orally disintegrating tablet market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The orally disintegrating tablet market size has grown strongly in recent years. It will grow from $14.88 billion in 2024 to $16.20 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to the increasing pediatric and geriatric populations, the rising prevalence of central nervous system disorders, the growing demand for convenient drug delivery methods, the increasing incidence of dysphagia, and the expanded utilization of outpatient care.
The orally disintegrating tablet market size is expected to see strong growth in the next few years. It will grow to $22.53 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to the rising burden of chronic diseases, growing preference for self-medication, increased penetration of telemedicine and e-pharmacies, heightened focus on personalized medicine, rising demand for vegan and allergen-free formulations, and an expanding elderly population. Key trends expected during this period include the development of multi-drug orally disintegrating tablets, integration with digital health platforms, innovations in packaging for enhanced stability and portability, advances in taste-masking technologies, and progress in formulation technology.
The increasing incidence of neurological disorders is expected to drive the growth of the orally disintegrating tablet (ODT) market in the coming years. Neurological disorders are medical conditions that impact the nervous system, including the brain and peripheral nerves, disrupting its normal function. This rise in neurological disorders is largely attributed to an aging population, as conditions such as Alzheimer's and Parkinson's become more prevalent with age, resulting in a growing number of cases. Orally disintegrating tablets offer significant benefits in managing neurological disorders by enabling easier and faster medication administration, particularly for individuals with dysphagia (difficulty swallowing) or cognitive impairments. These tablets support better treatment adherence, allow for timely dosing, and improve the overall effectiveness of therapy. For example, in March 2023, the Alzheimer's Association reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, with projections suggesting this number will rise to 13.8 million by 2060. As a result, the increasing prevalence of neurological disorders is fueling the growth of the orally disintegrating tablet market.
Leading companies in the orally disintegrating tablet market are focusing on innovations in drug formulation, particularly patient-centric drug delivery systems, to improve treatment adherence and outcomes. Patient-centric drug delivery systems are designed to make medications easier and more comfortable for patients to take, thereby improving their overall treatment experience and compliance. For instance, in May 2025, Viatris Inc., a US-based healthcare company, introduced Gen-Clozapine orally disintegrating tablets (ODT) in Canada, offering a new treatment option for individuals with treatment-resistant schizophrenia. As the first clozapine ODT available in Canada, it provides a convenient alternative that dissolves quickly in the mouth without the need for water, making it especially beneficial for patients with swallowing difficulties or adherence issues. The product is available in various strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), allowing for flexible and precise dose titration tailored to individual patient needs. Utilizing clozapine-the only approved antipsychotic for treatment-resistant schizophrenia-this ODT formulation aligns with established clinical protocols and enhances patient care.
In October 2022, Pfizer Inc., a US-based pharmaceutical company, acquired Biohaven Pharmaceuticals for an undisclosed amount. The acquisition was aimed at expanding Pfizer's internal medicine portfolio by incorporating Biohaven's innovative calcitonin gene-related peptide (CGRP) therapies. This includes NURTEC ODT (rimegepant), an orally disintegrating tablet approved for both the acute and preventive treatment of migraines in adults, along with other CGRP-related assets such as zavegepant and a pipeline of preclinical compounds. Biohaven Pharmaceutical Holding Company Ltd. is a US-based biopharmaceutical company specializing in the development and manufacturing of orally disintegrating tablets.
Major players in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy's Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions, and KalVista Pharmaceuticals Inc.
North America was the largest region in the orally disintegrating tablet market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in orally disintegrating tablet report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the orally disintegrating tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The orally disintegrating tablet market consists of sales of benadryl orally disintegrating tablets (diphenhydramine), zofran orally disintegrating tablets (ondansetron), cialis orally disintegrating tablets (tadalafil), and lamictal orally disintegrating tablets (lamotrigine). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Orally Disintegrating Tablet Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on orally disintegrating tablet market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for orally disintegrating tablet ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The orally disintegrating tablet market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Anti-Psychotics; Anti-Epileptics; Central Nervous System Stimulants; Anxiolytics; Anti-Parkinsonian Drugs; Anti-Hypertensives; Non-Steroidal Anti-Inflammatory Drugs; Anti-Allergy Drugs; Proton Pump Inhibitors; Other Drug Classes
2) By Disease Indication: Central Nervous System Disease; Gastrointestinal Disease; Cardiovascular System Disorders; Allergy; Other Disease Indications
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies; Drug Stores
4) By Consumer Type: Pediatric; Adult; Geriatric
Subsegments:
1) By Anti-Psychotics: Atypical Anti-Psychotics; Typical Anti-Psychotics
2) By Anti-Epileptics: Sodium Channel Blockers; GABA Analogs; Other Anti-Epileptics
3) By Central Nervous System Stimulants: Amphetamine Derivatives; Methylphenidate; Other CNS Stimulants
4) By Anxiolytics: Benzodiazepines; Non-Benzodiazepine Anxiolytics
5) By Anti-Parkinsonian Drugs: Dopamine Agonists; MAO-B Inhibitors; Other Anti-Parkinsonian Drugs
6) By Anti-Hypertensives: Beta-Blockers; Calcium Channel Blockers; ACE Inhibitors; Other Anti-Hypertensives
7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Diclofenac; Other NSAIDs
8) By Anti-Allergy Drugs: Antihistamines; Corticosteroids
9) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Other PPIs
10) By Other Drug Classes: Antiemetics; Antimigraine Drugs; Other Therapeutic Classes
Companies Mentioned: Pfizer Inc.; Merck & Co Inc.; Bayer AG; Bristol-Myers Squibb Company; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Otsuka Pharmaceutical Co Ltd.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Sun Pharmaceutical Industries Limited; Aurobindo Pharma USA Inc.; Dr. Reddy's Laboratories Limited; Cadila Healthcare Limited; Torrent Pharmaceuticals Limited; Adare Pharma Solutions; KalVista Pharmaceuticals Inc.
3. Orally Disintegrating Tablet Market Trends And Strategies
4. Orally Disintegrating Tablet Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Orally Disintegrating Tablet Growth Analysis And Strategic Analysis Framework
5.1. Global Orally Disintegrating Tablet PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Orally Disintegrating Tablet Market Growth Rate Analysis
5.4. Global Orally Disintegrating Tablet Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Orally Disintegrating Tablet Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Orally Disintegrating Tablet Total Addressable Market (TAM)
6.1. Global Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Psychotics
Anti-Epileptics
Central Nervous System Stimulants
Anxiolytics
Anti-Parkinsonian Drugs
Anti-Hypertensives
Non-Steroidal Anti-Inflammatory Drugs
Anti-Allergy Drugs
Proton Pump Inhibitors
Other Drug Classes
6.2. Global Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Central Nervous System Disease
Gastrointestinal Disease
Cardiovascular System Disorders
Allergy
Other Disease Indications
6.3. Global Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Drug Stores
6.4. Global Orally Disintegrating Tablet Market, Segmentation By Consumer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric
Adult
Geriatric
6.5. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anti-Psychotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Atypical Anti-Psychotics
Typical Anti-Psychotics
6.6. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anti-Epileptics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sodium Channel Blockers
GABA Analogs
Other Anti-Epileptics
6.7. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Central Nervous System Stimulants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amphetamine Derivatives
Methylphenidate
Other CNS Stimulants
6.8. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anxiolytics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Benzodiazepines
Non-Benzodiazepine Anxiolytics
6.9. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anti-Parkinsonian Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dopamine Agonists
MAO-B Inhibitors
Other Anti-Parkinsonian Drugs
6.10. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anti-Hypertensives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Beta-Blockers
Calcium Channel Blockers
ACE Inhibitors
6.11. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ibuprofen
Diclofenac
Other NSAIDs
6.12. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Anti-Allergy Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antihistamines
Corticosteroids
6.13. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Proton Pump Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Omeprazole
Esomeprazole
Other PPIs
6.14. Global Orally Disintegrating Tablet Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antiemetics
Antimigraine Drugs
Other Therapeutic Classes
7. Orally Disintegrating Tablet Market Regional And Country Analysis
7.1. Global Orally Disintegrating Tablet Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Orally Disintegrating Tablet Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Orally Disintegrating Tablet Market
9.1. China Orally Disintegrating Tablet Market Overview
9.2. China Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Orally Disintegrating Tablet Market
10.1. India Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Orally Disintegrating Tablet Market
11.1. Japan Orally Disintegrating Tablet Market Overview
11.2. Japan Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Orally Disintegrating Tablet Market
12.1. Australia Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Orally Disintegrating Tablet Market
13.1. Indonesia Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Orally Disintegrating Tablet Market
14.1. South Korea Orally Disintegrating Tablet Market Overview
14.2. South Korea Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Orally Disintegrating Tablet Market
15.1. Western Europe Orally Disintegrating Tablet Market Overview
15.2. Western Europe Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Orally Disintegrating Tablet Market
16.1. UK Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Orally Disintegrating Tablet Market
17.1. Germany Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Orally Disintegrating Tablet Market
18.1. France Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Orally Disintegrating Tablet Market
19.1. Italy Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Orally Disintegrating Tablet Market
20.1. Spain Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Orally Disintegrating Tablet Market
21.1. Eastern Europe Orally Disintegrating Tablet Market Overview
21.2. Eastern Europe Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Orally Disintegrating Tablet Market
22.1. Russia Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Orally Disintegrating Tablet Market
23.1. North America Orally Disintegrating Tablet Market Overview
23.2. North America Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Orally Disintegrating Tablet Market
24.1. USA Orally Disintegrating Tablet Market Overview
24.2. USA Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Orally Disintegrating Tablet Market
26.1. South America Orally Disintegrating Tablet Market Overview
26.2. South America Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Orally Disintegrating Tablet Market
27.1. Brazil Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Orally Disintegrating Tablet Market
28.1. Middle East Orally Disintegrating Tablet Market Overview
28.2. Middle East Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Orally Disintegrating Tablet Market
29.1. Africa Orally Disintegrating Tablet Market Overview
29.2. Africa Orally Disintegrating Tablet Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Orally Disintegrating Tablet Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Orally Disintegrating Tablet Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Orally Disintegrating Tablet Market Competitive Landscape And Company Profiles
